Skip to Main Content
Table 3

Renal-related adverse events after 9 months of treatment

Adverse eventPatients, n (%)
Zoledronic acid 4 mg* (n = 18)Zoledronic acid 8/4 mg* (n = 21)Placebo (n = 15)
Hyperuricemia 1 (5.6) 
Hematuria 1 (4.8) 1 (6.7) 
Renal failure NOS 1 (5.6) 
Blood creatinine increased 2 (9.5) 
Difficulty in micturition 1 (6.7) 
Hematuria present 1 (4.8) 
Obstructive uropathy 1 (4.8) 
Oliguria 1 (6.7) 
Acute renal failure 1 (4.8) 
Total patients 2 (11.1) 4 (19.0) 3 (20.0) 
Adverse eventPatients, n (%)
Zoledronic acid 4 mg* (n = 18)Zoledronic acid 8/4 mg* (n = 21)Placebo (n = 15)
Hyperuricemia 1 (5.6) 
Hematuria 1 (4.8) 1 (6.7) 
Renal failure NOS 1 (5.6) 
Blood creatinine increased 2 (9.5) 
Difficulty in micturition 1 (6.7) 
Hematuria present 1 (4.8) 
Obstructive uropathy 1 (4.8) 
Oliguria 1 (6.7) 
Acute renal failure 1 (4.8) 
Total patients 2 (11.1) 4 (19.0) 3 (20.0) 

NOTE. Cancer, Vol. 98, No. 5, 2003, pp. 962–9. Copyright © 2003 American Cancer Society. Reprinted by permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc. (6).

Abbreviation: NOS, Not otherwise specified.

*

Administered via 15-minute infusion.

Close Modal

or Create an Account

Close Modal
Close Modal